أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 460.52 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: titanium dioxide; carrageenan; lactose monohydrate; magnesium stearate; povidone; light magnesium oxide; macrogol 400; microcrystalline cellulose - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 172.695 mg (equivalent: quetiapine, qty 150 mg) - tablet, modified release - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; povidone; light magnesium oxide; microcrystalline cellulose; carrageenan; macrogol 400 - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 57.565 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: povidone; titanium dioxide; carrageenan; light magnesium oxide; lactose monohydrate; magnesium stearate; iron oxide red; macrogol 400; microcrystalline cellulose; iron oxide yellow - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, modified release - excipient ingredients: carrageenan; titanium dioxide; macrogol 400; microcrystalline cellulose; povidone; lactose monohydrate; magnesium stearate; iron oxide yellow; light magnesium oxide - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: carrageenan; macrogol 400; magnesium stearate; povidone; lactose monohydrate; light magnesium oxide; microcrystalline cellulose; iron oxide yellow; titanium dioxide - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. with three episodes in two years, there is no doubt it should be given. as a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. a major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. for these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; purified talc; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.